Effect of Nintedanib on Decline in Forced Vital Capacity (FVC) in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) by GAP Stage and ILD-GAP Index

被引：0
|
作者：
Kreuter, M. [1 ,2 ]
Highland, K. B. [3 ]
Nunes, H. [4 ]
Wuyts, W. A. [5 ]
Smith, V. [6 ]
Alves, M. [7 ]
Moros, L. [7 ]
Erhardt, E. [8 ]
Ryerson, C. J. [9 ,10 ]
机构：
[1] Heidelberg Univ, Ctr Rare Lung Dis Pneumol & Resp Care Med, Thoraxklin, Heidelberg, Germany
[2] German Ctr Lung Res, Heidelberg, Germany
[3] Cleveland Clin, Cleveland, OH 44106 USA
[4] Hop Avicenne, APHP, Dept Pulmonol, Bobigny, France
[5] Univ Hosp Leuven, Dept Pulm Med, Unit Interstitial Lung Dis, Leuven, Belgium
[6] Ghent Univ Hosp, Dept Rheumatol & Internal Med, Ghent, Belgium
[7] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[8] Mainanalytics GmbH, Sulzbach, Germany
[9] Univ British Columbia, Dept Med, Vancouver, BC, Canada
[10] Univ British Columbia, Ctr Heart Lung Innovat, Vancouver, BC, Canada
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2021年 / 203卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A1807
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Trajectories of Forced Vital Capacity (FVC) in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
    Distler, Oliver
    Vonk, Madelon
    Azuma, Arata
    Mayes, Maureen
    Khanna, Dinesh
    Highland, Kristin B.
    Toenges, Gerrit
    Alves, Margarida
    Allanore, Yannick
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 5170 - 5172
  • [2] Changes in FVC in the SENSCIS trial of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD)
    Highland, Kristin B.
    Azuma, Arata
    Fischer, Aryeh
    Kuwana, Masataka
    Maher, Toby M.
    Mayes, Maureen D.
    Raghu, Ganesh
    Girard, Mannaig
    Alves, Margarida
    Gahlemann, Martina
    Distler, Oliver
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [3] Changes in FVC in the SENSCIS Trial of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD)
    Kreuter, M.
    Highland, K. B.
    Azuma, A.
    Kuwana, M.
    Maher, T. M.
    Mayes, M. D.
    Raghu, G.
    Girard, M.
    Alves, M.
    Gahlemann, M.
    Distler, O.
    PNEUMOLOGIE, 2020, 74 : S56 - S57
  • [4] Decline in Forced Vital Capacity (FVC) in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) with and without Cough: Data from the SENSCIS Trial
    Kreuter, M.
    Volkmann, E. R.
    Hoffmann-Vold, A.
    Wijsenbeek, M. S.
    Smith, V.
    Khanna, D.
    Denton, C. P.
    Wuyts, W. A.
    Stock, C.
    Alves, M.
    Sambevski, S.
    Allanore, Y.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [5] Decline in forced vital capacity (FVC) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) with and without dyspnoea: data from the SENSCIS trial
    Kreuter, M.
    Volkmann, R. E.
    Hoffmann-Vold, A.
    Wijsenbeek, S. M.
    Smith, V
    Khanna, D.
    Denton, P. C.
    Wuyts, A. W.
    Miede, C.
    Alves, M.
    Sambevski, S.
    Allanore, Y.
    PNEUMOLOGIE, 2022, 76 : S19 - S20
  • [6] Decline in forced vital capacity (FVC) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) with and without cough: data from the SENSCIS trial
    Kreuter, M.
    Volkmann, R. E.
    Hoffmann-Vold, A.
    Wijsenbeek, S. M.
    Smith, V
    Khanna, D.
    Denton, P. C.
    Wuyts, A. W.
    Stock, C.
    Alves, M.
    Sambevski, S.
    Allanore, Y.
    PNEUMOLOGIE, 2022, 76 : S19 - S19
  • [7] DECLINE IN FORCED VITAL CAPACITY (FVC) IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD) WITH AND WITHOUT DYSPNOEA: DATA FROM THE SENSCIS TRIAL
    Volkmann, E.
    Kreuter, M.
    Hoffmann-Vold, A. M.
    Wijsenbeek, M.
    Smith, V.
    Khanna, D.
    Denton, C.
    Wuyts, W.
    Miede, C.
    Alves, M.
    Sambevski, S.
    Allanore, Y.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 101 - 102
  • [8] Associations Between Extent of Fibrotic Interstitial Lung Disease (ILD) and Forced Vital Capacity (FVC) at Baseline and Change in FVC in Subjects with Systemic Sclerosis-Associated ILD (SSc-ILD) in the SENSCIS Trial
    Denton, C.
    Goh, N.
    Humphries, S. M.
    Lynch, D. A.
    Maher, T. M.
    Spiera, R.
    Devaraj, A.
    Ho, L.
    Stock, C.
    Erhardt, E.
    Alves, M.
    Wells, A. U.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [9] Nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD): the SENSCIS trial
    Prasse, A.
    Distler, O.
    Highland, K. B.
    Gahlemann, M.
    Azuma, A.
    Mayes, M. D.
    Raghu, G.
    Sauter, W.
    Girard, M.
    Alves, M.
    Clerisme-Beaty, E.
    Kuwana, M.
    Maher, T. M.
    PNEUMOLOGIE, 2020, 74 : S57 - S58
  • [10] Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): The SENSCIS Trial
    Distler, O.
    Highland, K. B.
    Gahlemann, M.
    Azuma, A.
    Fischer, A.
    Mayes, M.
    Raghu, G.
    Sauter, W.
    Girard, M.
    Alves, M.
    Clerisme-Beaty, E.
    Kuwana, M.
    Maher, T. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
12345